WALTHAM, MA – EarlySense announced today that the company has received FDA Clearance for EarlySense 2.0 System, a newly designed Bedside Monitor for continuous measurement of respiration rate, heart rate and motion, in an automatic and contact-free manner.
"The newly designed Bedside Monitor is in line with EarlySense's constant focus on innovation and patient care improvements." said Dalia Argaman, VP of Clinical and Regulatory Affairs at EarlySense. "We provide the clinical team access to actionable information and empower them to identify potentially critical situations and respond in a proactive manner, in the hopes of preventing an adverse event from occurring as well as assisting the clinical team to become more efficient."
EarlySense is also enhancing its focus on Quality Assurance Tools and Benchmark Analysis Reports to provide sophisticated management tools that will allow hospital leaders to set quality goals, measure their results, drive staff behavior towards improvement and achieve their objectives. For example, providing the capabilities to measure staff response times to bed exit alerts, and then reviewing reports with staff has allowed several institutions to improve their response times, and thus reduce fall rates.
Mr. Avner Halperin, CEO of EarlySense added, "EarlySense plans to present a new product line to the market in the first quarter of 2014 that will address hospitals' needs for better patient supervision. The new product line will include safety focused product, addressing falls and pressure ulcers prevention, as well as EarlySense Respiratory and Heart Rate monitoring capability for early detection of patient deterioration."
For more information about EarlySense, visit http://www.earlysense.com.